$VIR insider trading
Over the last 12 months, Vir Biotechnology insiders reported no purchases and 38 sales totaling $21.0M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $21.0M 38 events
- Events · 12m
- 38 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Napolitano JanetD | ▼ Sale | 3,200 | $9.45 | $30K | -13.1% | plan |
| Jun 1, 2026 | Sabatini BrentSVP, Chief Accounting Officer · O | ▼ Sale | 379 | $9.45 | $4K | -0.6% | plan |
| May 1, 2026 | SATO VICKI LD | ▼ Sale | 22,000 | $10.05 | $221K | -2% | plan |
| Apr 6, 2026 | De Backer MariannePresident and CEO · O·D | ▼ Sale | 72,559 | $9.16 | $664K | -7.1% | plan |
| Apr 1, 2026 | SATO VICKI LD | ▼ Sale | 22,000 | $9.07 | $200K | -2% | plan |
| Mar 23, 2026 | Sabatini BrentSVP, Chief Accounting Officer · O | ▼ Sale | 7,711 | $9.12 | $70K | -11.1% | plan |
| Mar 2, 2026 | SATO VICKI LD | ▼ Sale | 22,000 | $9.51 | $209K | -1.9% | plan · 2 tranches |
| Feb 25, 2026 | Eisner MarkEVP and Chief Medical Officer · O | ▼ Sale | 3,505 | $9.69 | $34K | -2.2% | plan · 2 tranches |
| Feb 25, 2026 | de Verneuil VaninaEVP, General Counsel, Corp Sec · O | ▼ Sale | 16,817 | $9.77 | $164K | -13% | plan · 2 tranches |
| Feb 24, 2026 | SATO VICKI LD | ▼ Sale | 42,377 | $9.75 | $413K | -3.6% | plan · 2 tranches |
| Feb 24, 2026 | Sabatini BrentSVP, Chief Accounting Officer · O | ▼ Sale | 1,430 | $9.53 | $14K | -2% | plan |
| Feb 24, 2026 | O'Byrne JasonEVP & Chief Financial Officer · O | ▼ Sale | 1,634 | $9.53 | $16K | -1% | plan |
| Feb 24, 2026 | De Backer MarianneChief Executive Officer · O·D | ▼ Sale | 14,762 | $9.53 | $141K | -1.4% | plan |
| Feb 23, 2026 | Sabatini BrentSVP, Chief Accounting Officer · O | ▼ Sale | 1,829 | $7.45 | $14K | -2.5% | plan |
| Feb 23, 2026 | O'Byrne JasonEVP & Chief Financial Officer · O | ▼ Sale | 2,089 | $7.45 | $16K | -1.3% | plan |
| Feb 23, 2026 | Eisner MarkEVP and Chief Medical Officer · O | ▼ Sale | 2,089 | $7.45 | $16K | -1.3% | plan |
| Feb 23, 2026 | de Verneuil VaninaEVP, General Counsel, Corp Sec · O | ▼ Sale | 4,445 | $7.45 | $33K | -3.3% | plan |
| Feb 23, 2026 | De Backer MarianneChief Executive Officer · O·D | ▼ Sale | 19,039 | $7.45 | $142K | -1.8% | plan |
| Feb 13, 2026 | Sabatini BrentSVP, Chief Accounting Officer · O | ▼ Sale | 1,530 | $7.79 | $12K | -3.1% | plan |
| Feb 2, 2026 | SATO VICKI LD | ▼ Sale | 22,000 | $7.71 | $170K | -1.9% | plan |
| Jan 2, 2026 | SATO VICKI LD | ▼ Sale | 22,000 | $5.93 | $130K | -1.9% | plan |
| Dec 1, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 191,854 | $5.98 | $1.1M | -1.4% | plan · indirect |
| Dec 1, 2025 | SATO VICKI LD | ▼ Sale | 22,000 | $6 | $132K | -1.8% | plan |
| Nov 28, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 189,431 | $6.41 | $1.2M | -1.3% | plan · 2 tranches · indirect |
| Nov 25, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 463,774 | $6.27 | $2.9M | -3.2% | plan · 2 tranches · indirect |
| Nov 17, 2025 | O'Byrne JasonEVP & Chief Financial Officer · O | ▼ Sale | 6,799 | $5.56 | $38K | -5.8% | plan |
| Nov 5, 2025 | de Verneuil VaninaEVP, General Counsel, Corp Sec · O | ▼ Sale | 2,385 | $5.16 | $12K | -3% | plan |
| Nov 3, 2025 | de Verneuil VaninaEVP and General Counsel · O | ▼ Sale | 1,365 | $5.86 | $8K | -1.7% | plan |
| Nov 3, 2025 | SATO VICKI LD | ▼ Sale | 22,000 | $5.64 | $124K | -1.8% | plan |
| Oct 29, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 24,553 | $6.5 | $160K | -0.2% | plan · 2 tranches · indirect |
| Oct 27, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 113,099 | $6.01 | $680K | -0.8% | plan · 2 tranches · indirect |
| Oct 23, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 298,649 | $6.07 | $1.8M | -2% | plan · 2 tranches · indirect |
| Oct 21, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 330,210 | $6.23 | $2.1M | -2.2% | plan · 2 tranches · indirect |
| Oct 16, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 29,515 | $6.08 | $180K | -0.2% | plan · 2 tranches · indirect |
| Oct 10, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 251,360 | $6.14 | $1.5M | -1.6% | plan · 2 tranches · indirect |
| Oct 8, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 538,375 | $5.99 | $3.2M | -3.3% | plan · 2 tranches · indirect |
| Oct 6, 2025 | SVF Endurance (Cayman) Ltd10% | ▼ Sale | 524,297 | $5.57 | $2.9M | -3.1% | plan · 2 tranches · indirect |
| Oct 1, 2025 | SATO VICKI LD | ▼ Sale | 22,000 | $5.84 | $128K | -1.8% | plan |
| Sep 2, 2025 | SATO VICKI LD | ▼ Sale | 22,000 | $4.99 | $110K | -1.7% | plan |
Every $VIR filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Vir Biotechnology filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VIR feed.